Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Combotox (Imtox19/Imtox22)
i
Other names:
Imtox19/Imtox22, deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Abiogen, Montefiore Medical Center, National Cancer Institute
Drug class:
CD19 inhibitor, Protein synthesis inhibitor, CD22 inhibitor
Related drugs:
‹
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
MT-5111 (4)
omacetaxine mepesuccinate (4)
moxetumomab pasudotox (2)
recombinant (2)
MT-0169 (1)
LCB01-0371 (1)
MT-3724 (0)
OXS-1550 (0)
SVC112 (0)
oportuzumab monatox (0)
minocycline (0)
RSO-021 (0)
BL-22 (0)
epratuzumab (0)
IgG-RFB4-SMPT-dgA (0)
epratuzumab Y-90 (0)
REGN5837 (0)
TAC-001 (0)
JNJ-8780 (0)
blinatumomab (52)
tafasitamab-cxix (3)
A-319 (2)
FT596 (2)
CLN-978 (1)
YT-19 (1)
AFM11 (0)
ALA-101 (0)
AMG 562 (0)
AZD0486 (0)
BTN2A1/3A1-Fc-CD19scFv (0)
CAR-NK-CD19 cells (0)
CAR19-CYNK (0)
CB CAR-NK019 (0)
CD19.t-haNK (0)
CMG1A46 (0)
CNTY-101 (0)
ET-190 (0)
FT522 (0)
GNR-084 (0)
JD001 (0)
JD010 (0)
KN5501 (0)
NKX019 (0)
ONKT101 (0)
PIT565 (0)
QN-019a (0)
RG6333 (0)
RGV004 (0)
SNC103 (0)
TAC01-CD19 (0)
TAK-007 (0)
TC-110 (0)
TG-1801 (0)
inebilizumab-cdon (0)
YT-19/22 (0)
anti CD19/CD22 CAR NK cells (0)
autologous TRAC locus-inserted CD19-STAR-T (0)
dualCAR-NK19/70 (0)
GNC-038 (0)
RG6076 (0)
CF33-CD19 (0)
universal chimeric antigen receptor-modified AT19 cells (0)
MT-5111 (4)
omacetaxine mepesuccinate (4)
moxetumomab pasudotox (2)
recombinant (2)
MT-0169 (1)
LCB01-0371 (1)
MT-3724 (0)
OXS-1550 (0)
SVC112 (0)
oportuzumab monatox (0)
minocycline (0)
RSO-021 (0)
BL-22 (0)
epratuzumab (0)
IgG-RFB4-SMPT-dgA (0)
epratuzumab Y-90 (0)
REGN5837 (0)
TAC-001 (0)
JNJ-8780 (0)
›
Associations
News
Trials
Filter by
Latest
over3years
Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=10, Completed, Albert Einstein College of Medicine | Recruiting --> Completed | N=20 --> 10
over 3 years ago
Trial completion • Enrollment change
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
Combotox (Imtox19/Imtox22)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login